<DOC>
	<DOCNO>NCT02316171</DOCNO>
	<brief_summary>The study consist 2 sequential part . Part A study safety tolerability CAVATAK administer via intravesical instillation patient non-muscle invasive bladder cancer schedule undergo TUR . Part B evaluate safety tolerability CAVATAK administer sequential combination low dose Mitomycin C patient population .</brief_summary>
	<brief_title>Safety Clinical Activity CAVATAK™ Alone With Low Dose Mitomycin C Non-muscle Invasive Bladder Cancer</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Mitomycin</mesh_term>
	<mesh_term>Mitomycins</mesh_term>
	<criteria>Clinical diagnosis NMIBC base cystoscopic appearance ECOG 02 No intravesical therapy within 6 week study entry No prior radiation pelvis ANC &gt; 1500/mm³ ; Hb &gt; 9.0 g/dL ; Platelet &gt; 100000/mm³ Serum creatinine ≤ 1.5 mg/dL Bilirubin within normal limit ; AST ≤ 2.5x upper limit normal ( ULN ) ; ALT ≤ 2.5 x ULN ; alkaline phosphatase ≤ 2.5x ULN unless bone metastasis present absence liver metastasis INR &lt; 1.2 ; aPPT = 0.81.2 ; PT = 0.91.8 Candidate TUR plan undergo TUR Negative pregnancy test within 7 day treatment start Patients childbearing potential must agree use effective method birth control Prior local systemic treatment NMIBC Concurrent treatment chemotherapeutic agent Patients deem acceptable general anaesthesia Women pregnant lactate History vesicoureteric reflux indwell urinary stent Administration investigational agent within 3 month study entry Active cardiac disease Known infection HIV , hepatitis B C Active uncontrolled infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>